Stay updated on Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, potentially impacting ongoing medical research and treatment strategies.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:58.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section only indicated that no information was provided.
    Difference
    42%
    Check dated 2024-05-22T20:52:57.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:36:01.000Z thumbnail image

Stay in the know with updates to Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Abemaciclib Pembrolizumab in Head and Neck Cancer Clinical Trial page.